Scribe Therapeutics files for Nasdaq IPO to test appetite for early-stage biotech
TL;DR
Scribe Therapeutics filed for a Nasdaq IPO to gauge investor appetite for early-stage biotech and gene-editing startups, backed by major investors including RA Capital, Andreessen Horowitz, OrbiMed and Avoro Capital.
Topics:businessbiotech#biotech#biotech-funding#biotech-ipo#early-stage-biotech#gene-editing#scribe-therapeutics
- Scribe Therapeutics files for IPO in test of public appetite for earlier-stage biotechs Endpoints News
- Scribe Therapeutics Stockholders Include Eli Lilly Moomoo
- Scribe Therapeutics files for proposed Nasdaq IPO By Investing.com Investing.com South Africa
- Meet the gene-editing, cholesterol-fighting Alameda company looking for IPO riches The Business Journals
- SCTX IPO News - Cardiovascular diseases biotech Scribe Therapeutics files for a $75 million IPO renaissancecapital.com
Want the full story? Read the original reporting
Read on Endpoints News